The U.S. CTEPH Proceedings Enduring

ACTIVITY DESCRIPTION / STATEMENT OF NEED:

The United States CTEPH Proceedings 2021 provides a multidisciplinary framework for the evaluation and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). The activity compromises didactic presentations, debates, and panel discussions involving national and international experts in the field.

The content of this internet enduring material activity was originally presented as part of a live event. It is divided into three different learning activities, each with multiple videos. For each of the three activities, learners must view all videos in their entirety and complete a post-activity assessment and evaluation before they are eligible for continuing credit. 

TARGET AUDIENCE

This program has been designed to provide internists, pulmonologists, cardiologists, cardiovascular surgeons, interventional cardiologists and radiologists, anesthesiologists, thoracic radiologists, nurses, and allied healthcare professionals with state-of-the-art information to evaluate and manage patients with CTEPH.

LEARNING OBJECTIVES:

By the end of the session the participant will be able to:

  • Discuss an updated understanding of the pathophysiology of CTEPH and apply that information to a patient case
  • Describe the latest diagnostic and evaluative approaches to patients with suspected chronic thromboembolic disease and apply that information to a patient case
  • Discuss advances in pulmonary thromboendarterectomy for patients with chronic thromboembolic disease and CTEPH and apply that information to a patient case
  • Explain the role of balloon pulmonary angioplasty in the management of inoperable CTEPH and apply that information to a patient case
  • Define the role of medical therapy in selected patient groups with CTEPH and apply that information to a patient case

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ScientiaCME and NATF. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Physicians: ScientiaCME designates these internet enduring material activities for a maximum of 11.25 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistantsaccepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Pharmacists: ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ScientiaCME designates the following CTEPH modules for a maximum of 11.25 contact hour(s) (1.125 CEUs). Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire group of presentations and complete the course evaluation to receive continuing pharmacy education credit. The modules are listed as follows:

  • The United States CTEPH Proceedings 2021, Part 1: 0574-9999-21-010-H01-P: 4.5 contact hours (0.45 CEUs)
  • The United States CTEPH Proceedings 2021, Part 2: 0574-9999-21-041-H01-P: 2.25 contact hours (0.225 CEUs)
  • The United States CTEPH Proceedings 2021, Part 3: 0574-9999-21-042-H01-P: 4.5 contact hours (0.45 CEUs)

This is an Application (A)-type activity.

You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

The CPE statements of credit contain information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®

Participation in this activity is $99.00.

RELEASE DATE: December 15, 2021 — EXPIRATION DATE: December 14, 2022

AGENDA

The United States CTEPH Proceedings 2021, Part 1

VIDEO 1: Understanding CTEPH

Transition from Acute PE to CTEPH: Implications for Future Therapeutics?
Sudarshan Rajagopal, MD, PhD – Associate Professor, Duke University School of Medicine and Co-Director Pulmonary Vascular Disease Center, Duke University Medical Center

Screening for Chronic Thromboembolic Disease and CTEPH
F.A (Erik) Klok, MD, PhD – Specialist in Vascular Medicine, Leiden University Medical Center

The Ongoing Challenges of Diagnosing CTEPH
Gustavo Heresi, MD, MS – Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine and Director, Pulmonary Vascular and CTEPH Program, Cleveland Clinic
VIDEO 2: The Tools of Diagnosis

Advances in CT and MR Imaging: Implications for CTEPH Diagnosis and Management 
Deepa Gopalan, FRCP, FRCR – Senior Clinical Lecturer, Imperial College London and Associate Lecturer, University of Cambridge, UK

The Art of Pulmonary Angiography
Lori Daniels, MD, FACC – Professor of Medicine, UC San Diego and Medical Director Cardiovascular Intensive Care Unit, UC San Diego

Exercise Testing in Chronic PE
Paul Forfia, MD – Professor of Medicine, Temple University Hospital and Co-Director Pulmonary Hypertension, Right Heart Failure, CTEPH Program, Temple University Hospital
VIDEO 3: Interactive Case Presentations

Case 1: Symptomatic 6 Months Following a PE…What to Do?
Peter Hountras, MD – Assistant Professor Pulmonary & Critical Care Medicine, University of Colorado

Case 2: Is That Acute or Chronic Clot on CT?
Sonja Bartolome, MD – Professor, Internal Medicine, Pulmonary and Critical Care, UT Southwestern and Medical Director CTEPH Program, UT Southwestern

Case 3: VQ, CT, Pulmonary Angiogram…Is it All Necessary?
Victor M. Moles, MD – Clinical Assistant Professor, University of Michigan

The United States CTEPH Proceedings 2021, Part 2

VIDEO 4: Surgery and Surgical Management

Distal Endarterectomy in the Setting of Severe PH and High PVR: Should it be Done?
Marc de Perrot, MD, MSc – Professor of Surgery, University of Toronto and Director Toronto CTEPH Program Toronto General Hospital

“Thou Shall Not Reperfuse Diseased Lungs”: Endarterectomy in the Setting of COPD or Other Chronic Lung Diseases – Diagnostic and Technical Challenges
Jonathan Haft, MD – Robert H. Bartlett, MD Collegiate Professor of Cardiac Surgery, University of Michigan and Surgical Director, University of Michigan Hospital/Medical School

Pulmonary Endarterectomy After Previous BPA Sessions With and Without Stent Placement: So, What’s the Big Deal?
Michael Madani, MD, FACS – Professor of Surgery and Chief, Cardiovascular and Thoracic Surgery, University of California San Diego
VIDEO 5: Surgery and Surgical Management cont.

“May I ask for a different patient today?” What to do When Your Patient has HIT, Sickle Cell Anemia, Pulmonary Angiosarcoma, or is a Jehovah’s Witness
Victor Pretorius, MBChB – Professor of Clinical Surgery, University of California San Diego and Director of Heart Transplant and Mechanical Circulatory Support Programs, University of California San Diego

The Patient with CTED: To Operate or Not to Operate
Cameron Wright, MD – Mathisen Professor of Surgery, Harvard Medical School and Visiting Surgeon, Massachusetts General Hospital

Management of Complex Post-Op Complications – ECMO to the Rescue: Airway Bleeding, Severe Reperfusion Injury, Residual PH and RV Failure
Michael Tong, MD, MBA – Assistant Professor of Surgery, CCLCM, Case Western Reserve University and Surgical Director, Cleveland Clinic

The United States CTEPH Proceedings 2021, Part 3

VIDEO 6: Role of PH, targeted medical therapy, and BPA in management of inoperable CTEPH

Kenneth M. Moser Distinguished Scholar Lecture: The Challenges of Caring for CTEPH Patients in the U.S.
Kim M. Kerr, MD – Clinical Professor of Medicine, University of California San Diego and Vice Chief, Division of Pulmonary, Critical Care & Sleep Medicine, University of California San Diego

Inoperable CTEPH: Defining the Role of Medical Management
Alison Witkin, MD – Instructor, Harvard Medical School and Assistant in Medicine, Massachusetts General Hospital

The Hematology of CTEPH: Perioperative Consideration
Richard Channick, MD – Professor of Medicine, David Geffen School of Medicine at UCLA, Co-Director Pulmonary Vascular Disease Program, UCLA

Post-PTE Anticoagulation, Warfarin vs. DOACs: End of the INR?
Ivan Robbins, MD – Professor of Medicine, Vanderbilt University Medical Center

Life After PTE: Residual PH Assessment and Mechanical VTE Risk Mitigation
Anjali Vaidya, MD, FACC, FASE – Associate Professor of Medicine, Temple University Lewis Katz School of Medicine and Co-Director Pulmonary Hypertension, Right Heart Failure, CTEPH Program at Temple University Lewis Katz School of Medicine
VIDEO 7: Role of PH, targeted medical therapy, and BPA in management of inoperable CTEPH

The Great Debate: Distal CTEPH – Getting to the Root of the Problem: PTE or BPA?
Michael Madani, MD, FACS – Professor of Surgery and Chief, Cardiovascular and Thoracic Surgery, University of California San Diego
Robert Frantz, MD – Professor of Medicine, Mayo Clinic

Technical Considerations and Challenges in BPA
Riyaz Bashir, MD – Professor of Medicine, Temple University Hospital and Director of Cardiovascular Diseases, Temple University Hospital

BPA: How Much BPA is Enough? Targets, Goals, and Limitations
Richard Krasuski, MD – Professor of Medicine and Pediatrics, Duke University and Medical Director CTEPH Program, Duke University

BPA After PTE: Whether to Consider, When to do it?
Kenneth Rosenfield, MD – Faculty, Harvard Medical School and Section Head, Vascular Medicine and Intervention, Massachusetts General Hospital
VIDEO 8: Role of PH, targeted medical therapy, and BPA in management of inoperable CTEPH

Handling Vessel Injury and Hemoptysis After a BPA
David Poch, MD

BPA Combined with Medical Management in Inoperable CTEPH
Vladimir Lakhter, DO, SVM – Assistant Professor of Medicine, Temple University Hospital Lewis Katz School of Medicine and Interventional Cardiology, Temple University Hospital Lewis Katz School of Medicine

FACULTY DISCLOSURES AND RESOLUTION OF COI

William R. Auger, MD, FCPP: Consultant – Bayer, Janssen PH, Cereno Scientific

Sonja Bartolome, MD: Consultant – Janssen

Riyaz Bashir, MD: Stock Holder – Thromboelx, Inc.

Todd Bull, MD: Consultant – Bayer; Researcher – Johnson & Johnson, United Therapeutics, Actelion

Richard Channick, MD: Speaker – Actelion, Bayer; Advisor – Actelion, Bayer, Gossamer, Third Pole, Aria CV, Acceleron

Michael Cuttica, MD: Consultant – Bayer, Janssen, United Therapeutics

Paul Forfia, MD: Consultant – Bayer, Janssen, United Therapeutics

Deepa Gopalan, FRCP, FRCR: Speaker – Bayer Pharma AG

Gustavo Heresi, MD: Consultant – non-branded Speakers Bureau – Bayer; Consultant – Janssen

Kim M. Kerr, MD: Research Support – Bayer; Consultant – Actelion

F.A. Klok, MD, PhD: Unrestricted Research Support – Bayer, Actelion, BSCI

Michael Madani, MD: Consultant – Bayer/Merck, Janssen/Actelion, Wexler Surgical

Vallerie McLaughlin, MD: Grant support – Acceleron, Janssen, Sonovie, United Therapeutics; Scientific Consulting – Acceleron, Aerovate, Altavant, Bayer, Caremark, Civi Biopharma, Corvista, Gossamer Bio, Janssen, Mark, United Therapeutics

David Poch, MD: Investigator – Janssen, United Therapeutics, Phase Bio, Acceleron

Ivan Robbins, MD: Advisory Board, PI – Bayer; PI – Complexa, Inc.; PI – Altavant Sciences; Advisory Board PI – Acceleron Pharma

Josanna Rodriguez-Lopez, MD: Consultant/Research – Bayer, United Therapeutics, Actelion; Consultant – Altavant

Kenneth Rosenfield, MD: Consultant/Scientific Advisory Board: Althea Medical, Angiodynamics; Boston Scientific; Contego; InspireMD; Magneto; Mayo Clinic; Neptune Medical; Philips; Summa Therapeutics; Surmodics; Thrombolex; Terumo; Truvic; Grants to my Institution: NIH; Boston Scientific; Equity: Accolade; Access Vascular; Althea Medical; Contego; Cruzar Systems; Embolitech; Endospan; InspireMG; JanaCare; Magneto; Orchestra; PQ Bypass; Prosomnus; Shockwave; Summa Therapeutics; Thrombolex; Truvic; Valcare; Board Member: National PERT Consortium, a nonprofit 501c3 organization dedicated to advancing treatment and improving outcomes in pulmonary embolism

Anjali Vaidya, MD: Consultant, Speaker Bureau: Bayer

Alison Witkin, MD: Advisory Board, United Therapeutics

Individuals with no conflicts of interest to disclose: 

  • Content reviewer: Charles J Turck, PharmD, BCPS, BCCCP, Presidenti, ScientiaCME
  • Lori Daniels, MD, FACC
  • Marc de Perrot, MD, MSc
  • Jonathan Haft, MD
  • Peter Hountras, MD
  • Richard Krasuski, MD
  • Vladimir Lakhter, DO, SVM
  • Victor M. Moles, MD
  • Victor Pretorius, MBChB
  • Sudarshan Rajagopal, MD, PhD
  • Michael Tong, MD, MBA
  • Cameron Wright, MD

INSTRUCTIONS:

  • Read the learning objectives above.
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately. 

SYSTEM REQUIREMENTS

PC

MAC

  • Windows 7 or above
  • Internet Explorer 8
  • *Adobe Acrobat Reader
  • Safari or Chrome or Firefox
  • *Adobe Acrobat Reader
  • Internet Explorer is not supported on Macintosh

*Required to view Printable PDF Version

Related Articles